The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use
Patients who participate in randomized clinical trials and define the effectiveness and safety of the treatments, are carefully selected and therefore do not allow us to extrapolate the results to our patients in usual clinical practice environments.
Studies are necessary to know the effectiveness and safety of interventions, outside the restrictive conditions of clinical trials. Studies based on real data, RWD, are investigations based on data from patients and their treatments collected during the routine management of a pathology, under the usual conditions of clinical practice. RWD studies help to collect additional information on patient populations that are often poorly represented or not represented in clinical trials at all.
Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis are autoimmune systemic diseases characterized by inflammation, pain and joint degeneration. The main objective of treating these pathologies is the control and / or remission of the disease
The objective of this study is to evaluate, under the actual conditions of use, dosing patterns of adalimumab, etanercept, golimumab and infliximab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and to compare them with the regimens recommended by products labels, as well as evaluating the financial implications of these regimen modification.
Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, Broto-Sumalla A, Burgos-SanJosé A, Climent-Bolta C, et al. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Rev Pharmacoecon Outcomes Res. 2015 May 14;1–8.